Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls

Background: Carfilzomib, an irreversible proteasome inhibitor approved for the treatment of relapsed/refractory Multiple Myeloma (MM) has been associated with Thrombotic Microangiopathy (TMA). Several pathogenetic mechanisms of carfilzomib-induced TMA have been proposed; however, recently, there has...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriilaki, Eleni, Dalampira, Dimitra, Theodorakakou, Foteini, Liacos, Christine-Ivy, Kanellias, Nikolaos, Eleutherakis-Papaiakovou, Evangelos, Terpos, Evangelos, Gavriatopoulou, Maria, Verrou, Evgenia, Triantafyllou, Theodora, Sevastoudi, Aggeliki, Koravou, Evaggelia-Evdoxia, Touloumenidou, Tasoula, Varelas, Christos, Papalexandri, Apostolia, Sakellari, Ioanna, Dimopoulos, Meletios A., Kastritis, Efstathios, Katodritou, Eirini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225266/
https://www.ncbi.nlm.nih.gov/pubmed/35743426
http://dx.doi.org/10.3390/jcm11123355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225266/
https://www.ncbi.nlm.nih.gov/pubmed/35743426
http://dx.doi.org/10.3390/jcm11123355

Ejemplares similares